Photo: rachel wisniewski/Reuters AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer.

AstraZeneca and Daiichi Sankyo have earned their second FDA approval for Datroway, scoring a nod for the drug to treat EGFR-mutated non-small cell lung cancer.

Ken Keller, global head of oncology business, and president and CEO, Daiichi Sankyo, Inc, said: “With today’s accelerated approval, Datroway is now the first TROP2-directed medicine available for ...

Support Supported by Daiichi Sankyo Company, Limited, and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ; and by Daiichi Sankyo, Inc (U31402-A-U102).

Facioscapulohumeral muscular dystrophy (FSHD) often starts with muscle weakness in the face, shoulders, and upper arms, and ...

According to the latest study from BCC Research, "The Global Influenza Market" is expected to grow from $9.0 billion in 2024 ...

According to DelveInsight's analysis, the market for facioscapulohumeral muscular dystrophy is anticipated to increase during the forecast period (2025-2034), owing to improved diagnosis, treatment ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer.

MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan (I-DXd) against docetaxel in individuals with metastatic ...

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...

S&T Bancorp, Inc. (S&T) (NASDAQ: STBA), the holding company for S&T Bank, announced today that a conference call detailing the company's second quarter 2025 earnings will be held live via webcast ...

LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), the leading whole-person wellbeing solution for employers, health plans and other organizations, is pleased to announce the completion of ...